HPPDL Inhibitors
HPPDL inhibitors are a class of chemical compounds that inhibit the activity of the enzyme Hydroxyphenylpyruvate Dioxygenase-Like (HPPDL). This enzyme is part of a family of dioxygenases, which are known for their role in catalyzing the incorporation of oxygen into organic substrates. HPPDL, in particular, has been identified for its unique enzymatic characteristics, which involve the manipulation of specific biochemical pathways in organisms. The inhibition of HPPDL by these compounds leads to alterations in the normal functioning of these pathways, which can have a range of biochemical implications.
From a chemical standpoint, HPPDL inhibitors are often characterized by their ability to bind to the active site of the HPPDL enzyme, thereby preventing its normal interaction with substrates. This binding is typically achieved through molecular structures that mimic the enzyme's natural substrates or intermediate states in its catalytic cycle, effectively blocking the enzymatic activity. The development of HPPDL inhibitors typically involves a multidisciplinary approach, combining elements of organic chemistry, biochemistry, and computational modeling. The process starts with the synthesis of potential inhibitory compounds, followed by in vitro testing to assess their efficacy in inhibiting HPPDL. This is often accompanied by computational modeling to predict how these compounds interact with the enzyme at a molecular level. Furthermore, studies on the physical and chemical properties of these inhibitors, such as solubility, stability, and reactivity, are crucial in understanding their behavior in different environments. Advanced analytical techniques, such as mass spectrometry and chromatography, are employed to characterize these compounds and assess their purity and composition. Overall, HPPDL inhibitors represent a significant area of interest in the field of enzyme inhibition, providing insights into the complex mechanisms of enzyme function and regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Triclabendazole | 68786-66-3 | sc-213105 sc-213105A | 100 mg 1 g | $106.00 $122.00 | ||
Inhibits tubulin polymerization in parasites. In mammalian cells, this can disturb microtubule dynamics, which is crucial for intracellular transport processes, including those that involve HPPDL localization and function. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Binds to tubulin, preventing its polymerization and thereby disrupting microtubule formation. This action can indirectly diminish HPPDL distribution and function, which relies on intact cytoskeleton structures for proper cellular localization and activity. | ||||||
Taxol | 33069-62-4 | sc-201439D sc-201439 sc-201439A sc-201439E sc-201439B sc-201439C | 1 mg 5 mg 25 mg 100 mg 250 mg 1 g | $41.00 $74.00 $221.00 $247.00 $738.00 $1220.00 | 39 | |
Stabilizes microtubules and prevents their depolymerization, which can impede intracellular trafficking and the cellular processes dependent on microtubule dynamics, including those associated with HPPDL function. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Inhibits microtubule assembly by binding to tubulin, which could lead to a reduction in HPPDL transport or localization to specific intracellular compartments, ultimately decreasing its functional activity. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Destabilizes microtubules by binding to beta-tubulin and inhibiting polymerization, potentially impacting the intracellular positioning and function of HPPDL. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Inhibits transport of proteins from the endoplasmic reticulum to the Golgi apparatus, which may lead to improper processing and functioning of HPPDL by preventing its correct post-translational modification. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that alters intracellular ion gradients, particularly sodium and hydrogen ions. This disruption can affect pH-dependent processes and may indirectly reduce HPPDL’s activity due to altered ionic homeostasis within its functional compartments. | ||||||
Oligomycin | 1404-19-9 | sc-203342 sc-203342C | 10 mg 1 g | $149.00 $12495.00 | 18 | |
Targets ATP synthase in mitochondria, reducing ATP production. Since ATP is necessary for many cellular functions, this can indirectly decrease HPPDL activity due to reduced energy availability for its functioning. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
A glycolysis inhibitor that can lead to decreased ATP levels, indirectly diminishing the energy-dependent processes required for HPPDL function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation in the endoplasmic reticulum. As glycosylation can be crucial for the function of some proteins, if HPPDL is glycosylated, its activity could be reduced due to the absence of proper glycosylation. | ||||||